One of the current gaps in current #breastcancer research is whether or not to do routine screening for brain metastases in patients with metastatic breast cancer who don’t have any concerning symptoms for brain metastases. Historically, we did not screen for brain metastases because therapies were toxic and we didn’t have good therapies but things are changing w better therapies (although we still have a way to go). This has raised the question of whether we should do brain imaging in people w

The National Comprehensive Cancer Network® (NCCN®), an alliance of 21 world-leading cancer centers dedicated to improving the quality and effectiveness of care provided to patients with cancer, has updated its guidelines for breast cancer. The Oncotype DX® test is now the only test classified as “preferred” with the highest level of evidence for node-negative and postmenopausal node-positive breast cancer patients. Read more: https://exas.co/2QRSRWU | Exact Sciences